Critical Comparison: IntelGenx Technologies (OTCMKTS:IGXT) vs. Theravance Biopharma (NASDAQ:TBPH)

IntelGenx Technologies (OTCMKTS:IGXTGet Rating) and Theravance Biopharma (NASDAQ:TBPHGet Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for IntelGenx Technologies and Theravance Biopharma, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IntelGenx Technologies 0 0 0 0 N/A
Theravance Biopharma 1 0 2 0 2.33

Theravance Biopharma has a consensus price target of $14.67, suggesting a potential upside of 33.09%. Given Theravance Biopharma’s higher probable upside, analysts clearly believe Theravance Biopharma is more favorable than IntelGenx Technologies.

Volatility and Risk

IntelGenx Technologies has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.

Profitability

This table compares IntelGenx Technologies and Theravance Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IntelGenx Technologies -850.04% -863.97% -70.29%
Theravance Biopharma 1,646.84% N/A -14.98%

Earnings and Valuation

This table compares IntelGenx Technologies and Theravance Biopharma’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IntelGenx Technologies $1.53 million 25.35 -$9.32 million ($0.08) -2.78
Theravance Biopharma $55.31 million 13.42 -$199.43 million $11.26 0.98

IntelGenx Technologies has higher earnings, but lower revenue than Theravance Biopharma. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Theravance Biopharma beats IntelGenx Technologies on 8 of the 11 factors compared between the two stocks.

About IntelGenx Technologies

(Get Rating)

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

About Theravance Biopharma

(Get Rating)

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.

Receive News & Ratings for IntelGenx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.